KIRhub 2.0· v2

Upadacitinib

40fa62a5-8aa0-57b9-8d0f-4337407620bb · FDA Approved · targets JAK1

Upadacitinib

MeasuredReference

Upadacitinib targets RAF1, JAK2, JAK3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RAF1 JAK2 JAK3 JAK1 TYK2

Top hallmarks

tumor promoting inflammation3.6k
evading apoptosis2.2k
proliferation2.2k

Top pathways disrupted

pi3k akt mtor signaling5.7k
allograft rejection5.3k
apical junction5.3k

Resistance landscape — Upadacitinib

MeasuredReference

2 known oncogenic variants exist on Upadacitinib's top targets — see detail for inhibition impact.

RAF1 1 known variant
- RAF1 (R391W)
JAK2 1 known variant
- JAK2 (V617F)

Open in new tab